YS 2051
Latest Information Update: 26 Mar 1998
Price :
$50 *
At a glance
- Originator Yason
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 26 Mar 1998 No-Development-Reported for Immunological disorders in Italy (PO)
- 29 Apr 1997 New profile
- 20 Feb 1997 Preclinical development for Immunological disorders in Italy (PO)